Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 19 of the 43 sources its claims cite were checked for support.

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Open access
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., Kelmendi, B. · 2025 · Frontiers in Psychiatry

Abstract

Introduction: The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative study of participant experiences from the first randomized placebo-controlled trial of single-dose psilocybin combined with unstructured and non-directive support for individuals with treatment-refractory OCD. Our research explored how participants experienced acute and post-dosing effects, the interrelationships between these effects, and participants’ perspectives on therapeutic change. Materials and methods: We conducted qualitative interviews with 12 participants approximately one month after psilocybin dosing; (six who received psilocybin in the initial randomized placebo-controlled phase, six who received open-label psilocybin following unblinding). We analyzed interview transcripts via interpretative phenomenological analysis (IPA) and engaged in consensus decision-making to arrive at 100% intercoder agreement in the process of abstracting codes into higher-order themes. Results: Four major themes (and several subthemes) emerged from our analysis: 1) Influences on Psilocybin Experience (i.e., Set, Setting); 2) Acute Effects (i.e., Acute perceptual effects, Acute [meta]cognitive effects, Acute emotional effects, Acute impact of OCD, Other acute effects); 3) Post-Dosing Changes in OCD (i.e., Post-dosing changes in symptoms, Post-dosing changes in perceptions of OCD); as well as 4) Post-Dosing Changes Beyond OCD Symptoms (i.e., Post-dosing [meta]cognitive changes, Other post-dosing changes). Meaningful interrelationships among codes, subthemes, and themes were the norm. Discussion: Our findings highlight the moderate to strong influences of set and setting in the nature and trajectory of participants’ psilocybin experiences. We also uncovered acute, synergistic visual/perceptual, emotional/psychological, and physiological/somatic effects that map onto those commonly reported in prior psilocybin trials for other closely related indications. However, these acute effects tended to occur at lower intensities (i.e., ‘partial’ experiences) potentially due to acute interference by OCD symptoms. Certain acute and post-dosing (meta)cognitive and behavioral effects also map onto putative mechanisms of action in evidence-based psychotherapy for OCD (e.g., exposure and response prevention [ERP] and acceptance and commitment therapy [ACT]). These findings yielded hypotheses for future investigation, and point toward potential integration of psilocybin with structured psychotherapy approaches for OCD. Copyright © 2025 Ching, Stahnke, Shnayder, Agin-Liebes, Adams, Amoroso, Baiz, Belser, Bohner, Burke, D’Amico, DePalmer, Eilbott, Fram, Grazioplene, Hokanson, Jankovsky, Kichuk, Martins, Purohit, Schaer, Sierra, Witherow, Pittenger and Kelmendi.

Overview

CoChat Summary

## TL;DR

This qualitative IPA study analyzed 12 post-dosing interviews from a randomized, double-blind, placebo-controlled psilocybin trial for treatment-refractory OCD and found that set/setting strongly shaped experiences. Participants commonly reported acute perceptual, emotional, and (meta)cognitive effects, with heterogeneous post-dosing OCD changes and several parallels to ACT/ERP-style processes.

## Key findings

  • The analysis identified 4 major themes: (1) Influences on Psilocybin Experience, (2) Acute Effects, (3) Post-Dosing Changes in OCD, and (4) Post-Dosing Changes Beyond OCD Symptoms.
  • The sample showed heterogeneous OCD outcomes after dosing: some participants had full remission of obsessions/compulsions (e.g., Participants 6 and 8), some had brief total symptom relief with symptoms returning days later (Participants 13, 16, 17), and others had persistent but positively changed relationships with their symptoms.
  • The paper reports moderate to strong influences of set and setting, with support from facilitators, the room, and music shaping the trajectory of the experience; these factors were described as instrumental for trust, comfort, and insight.
  • Acute experiences were often “partial” mystical experiences rather than full ones, which the authors suggest may reflect OCD interference; they also note many acute and post-dosing processes resembled ACT and ERP mechanisms such as decentering, mindfulness, cognitive defusion, experiential approach, and reduced avoidance.

## Methods

  • Qualitative study nested within the first randomized, double-blind, placebo-controlled trial of single-dose psilocybin for treatment-refractory OCD, with unstructured, non-directive psychological support; the paper also references an open-label phase after unblinding.
  • Conducted semi-structured interviews with 12 treatment completers approximately one month after psilocybin dosing: 6 from the initial randomized placebo-controlled phase and 6 who later received open-label psilocybin.
  • Analyzed transcripts using interpretative phenomenological analysis (IPA) with consensus decision-making and 100% intercoder agreement; the authors say data saturation stopped producing new categories after the 10th interview.

## Limitations

  • The paper states limitations of retrospective data collection at a single timepoint rather than real-time micro-longitudinal assessment, which could better capture change over time.
  • The authors note the convenience sample of the first 12 completers may not represent the full range of psilocybin experiences, especially those who withdrew or declined interview.
  • The paper also states the sample was demographically homogenous, limiting transferability; more diverse narratives are needed to better capture the role of identity/set in psilocybin effects.
  • Evident from the text: because the study is qualitative and focused on 12 participants, it cannot support causal claims about psilocybin’s effects on OCD.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2025.1726818

Cites

84 of 85 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Simplified study flow diagram.
Figure 1 Simplified study flow diagram.CC BY · PubMed Central
Figure 2 Summary of IPA process.
Figure 2 Summary of IPA process.CC BY · PubMed Central
Figure 3 Major themes (black ovals), subthemes (gray ovals), and codes (white boxes) emergent from interview data. Interrelationships at all levels (i.e., within and between codes, subthemes, and themes) were the norm. For simplicity, we highlighted salient links with unidirectional and bidirectional arrows in this figure and detailed the rest in the text.
Figure 3 Major themes (black ovals), subthemes (gray ovals), and codes (white boxes) emergent from interview data. Interrelationships at all levels (i.e., within and between codes, subthemes, and themes) were the norm. For simplicity, we highlighted salient links with unidirectional and bidirectional arrows in this figure and detailed the rest in the text.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 1 Not valid · 5 Not checked · 64 Own results and interpretations

37 more claims

Create a free account to see all 78 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 13
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 83 references

Research works printed but not linked: 3

  1. Hayes, 2016, Acceptance and commitment therapy: The process and practice of mindful change
  2. Yaden, 2022, The varieties of
  3. Thompson, 2023, ACT-informed exposure for anxiety: creating effective, innovative, and values-based exposures using acceptance and commitment therapy

Cited by

See all 6

Metadata

Authors
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., & Kelmendi, B.
Affiliations
  • Yale University (US)
  • East Tennessee State University (US)
  • New York University (US)
Corresponding author
Ching, T. H. W.
Venue
Frontiers in Psychiatry
Published
2025-12-10
Volume
16
Pages
1726818-1726818
ISSN
1664-0640 (ISSN-L)
OpenAlex
W7113899315
Cited by
6
References
83
Citations by year
2026: 6
FWCI
7.04
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Yale University
  • Usona Institute
  • National Institute of Mental Health (K23MH122777)
  • Yale Center for Clinical Investigation, Yale School of Medicine
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psilocybin, obsessive-compulsive disorder, treatment-refractory OCD, subjective effects, set and setting, emotional impact, therapeutic change, psychedelic-assisted psychotherapy, exposure and response prevention, acceptance and commitment therapy, participant experiences

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. https://app.cochat.ai/papers/10.3389/fpsyt.2025.1726818
The paper
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., . . . Kelmendi, B. (2025). Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1726818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.